The three new patents add to the company's existing portfolio and extend protection of the company's proprietary transdermal technology through at least 2028. Agile has also received a notice of allowance from the USPTO for the trademark Twirla(TM), and conditional acceptance from the FDA to use the proprietary name "Twirla" for its AG200-15 contraceptive patch, pending final agency review prior to NDA approval.
"We are thrilled that the USPTO issued these additional patents -- it underscores the proprietary nature of our transdermal technology and enhances the value of our intellectual property estate," said Al Altomari, President and CEO of Agile Therapeutics. "We are continuing to develop our patent portfolio in key markets around the world and the expansion in the U.S. is a great step forward."
Agile Therapeutics announces three new U.S. patents on its technology and the brand name Twirla(TM) for its first contraceptive patch
Agile Therapeutics today announced that the U.S. Patent and Trademark Office (USPTO) has issued three new patents with claims related to its contraceptive patch technology.
Aug 31, 2012
Companies in this article
Recommended
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
